Search research articles
Contact Us
Filters
Showing results (151-160 of 185) with videos related to
Page
of 19
Sort By:
Clinical Pharmacology and Therapeutics
|
December 22, 2016
Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity
Blessy George, Xia Wen, Nickie Mercke, et al.
European Journal of Clinical Pharmacology
|
August 12, 2009
CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases
Melanie S Joy, Kimberly Dornbrook-Lavender, Joyce Blaisdell, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
October 20, 2023
DLG2 intragenic exonic deletions reinforce the link to neurodevelopmental disorders and suggest a potential association with congenital anomalies and dysmorphism
Yunjia Chen, Ender Karaca, Nathaniel H Robin, et al.
European Journal of Clinical Pharmacology
|
June 23, 2010
Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis
Melanie S Joy, Tammy Boyette, Yichun Hu, et al.
International Journal of Molecular Sciences
|
June 23, 2017
Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin
Cara Chang, Yichun Hu, Susan L Hogan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
June 16, 2005
Clinical pharmacists as multidisciplinary health care providers in the management of CKD: a joint opinion by the Nephrology and Ambulatory Care Practice and Research Networks of the American College of Clinical Pharmacy
Melanie S Joy, Renee M DeHart, Cheryl Gilmartin, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
December 17, 2008
Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group
Melanie S Joy, Debbie S Gipson, Mary Dike, et al.
Drug Delivery and Translational Research
|
July 29, 2021
An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis
Uma Fogueri, Georgia Charkoftaki, Gavriel Roda, et al.
Pharmacotherapy
|
September 17, 2013
In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases
Melanie S Joy, Reginald F Frye, Thomas D Nolin, et al.
AAPS Open
|
August 29, 2025
Bardoxolone methyl improves survival and reduces clinical measures of kidney injury in tumor-bearing mice treated with cisplatin
Lauren E Thompson, Stacey M Tuey, Paola Garcia Gonzalez, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 185) with videos related to
Sort By:
Page
of 19
Clinical Pharmacology and Therapeutics
|
December 22, 2016
Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity
Blessy George, Xia Wen, Nickie Mercke, et al.
European Journal of Clinical Pharmacology
|
August 12, 2009
CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases
Melanie S Joy, Kimberly Dornbrook-Lavender, Joyce Blaisdell, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
October 20, 2023
DLG2 intragenic exonic deletions reinforce the link to neurodevelopmental disorders and suggest a potential association with congenital anomalies and dysmorphism
Yunjia Chen, Ender Karaca, Nathaniel H Robin, et al.
European Journal of Clinical Pharmacology
|
June 23, 2010
Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis
Melanie S Joy, Tammy Boyette, Yichun Hu, et al.
International Journal of Molecular Sciences
|
June 23, 2017
Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin
Cara Chang, Yichun Hu, Susan L Hogan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
June 16, 2005
Clinical pharmacists as multidisciplinary health care providers in the management of CKD: a joint opinion by the Nephrology and Ambulatory Care Practice and Research Networks of the American College of Clinical Pharmacy
Melanie S Joy, Renee M DeHart, Cheryl Gilmartin, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
December 17, 2008
Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group
Melanie S Joy, Debbie S Gipson, Mary Dike, et al.
Drug Delivery and Translational Research
|
July 29, 2021
An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis
Uma Fogueri, Georgia Charkoftaki, Gavriel Roda, et al.
Pharmacotherapy
|
September 17, 2013
In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases
Melanie S Joy, Reginald F Frye, Thomas D Nolin, et al.
AAPS Open
|
August 29, 2025
Bardoxolone methyl improves survival and reduces clinical measures of kidney injury in tumor-bearing mice treated with cisplatin
Lauren E Thompson, Stacey M Tuey, Paola Garcia Gonzalez, et al.
Page
of 19